AxoGen to Host Third Annual Analyst and Investor Day on November 19, 2018
November 06 2018 - 7:00AM
AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and
marketing innovative surgical solutions for damage or discontinuity
to peripheral nerves, today announced that it will host its
Third Annual Analyst and Investor Day on Monday,
November 19, 2018 in New York City from 11:30 a.m. – 3:30 p.m. ET.
AxoGen executives and surgeon thought leaders will discuss the
company’s comprehensive platform for peripheral nerve repair and
the emerging nerve repair market.
The program portion of the event will be webcast
live beginning at 12:00 noon and can be accessed through the
Investors page at www.axogeninc.com. For those not available to
listen to the live broadcast, a replay will be archived for 90 days
and available through the Investors page on www.axogeninc.com. For
more information or to RSVP please contact
AxoGenEvents@troutgroup.com.
About AxoGenAxoGen (AXGN) is the
leading company focused specifically on the science, development
and commercialization of technologies for peripheral nerve
regeneration and repair. We are passionate about helping to restore
peripheral nerve function and quality of life to patients with
physical damage or discontinuity to peripheral nerves by providing
innovative, clinically proven and economically effective repair
solutions for surgeons and health care providers. Peripheral nerves
provide the pathways for both motor and sensory signals throughout
the body. Every day, people suffer traumatic injuries or undergo
surgical procedures that impact the function of their peripheral
nerves. Physical damage to a peripheral nerve, or the
inability to properly reconnect peripheral nerves, can result in
the loss of muscle or organ function, the loss of sensory feeling,
or the initiation of pain.
AxoGen's platform for peripheral nerve repair
features a comprehensive portfolio of products, including Avance®
Nerve Graft, an off-the-shelf processed human nerve allograft for
bridging severed peripheral nerves without the comorbidities
associated with a second surgical site, AxoGuard® Nerve Connector,
a porcine submucosa extracellular matrix (ECM) coaptation aid for
tensionless repair of severed peripheral nerves, AxoGuard® Nerve
Protector, a porcine submucosa ECM product used to wrap and protect
damaged peripheral nerves and reinforce the nerve reconstruction
while preventing soft tissue attachments, and Avive® Soft
Tissue Membrane, a minimally processed human umbilical cord
membrane that may be used as a resorbable soft tissue covering to
separate tissue layers and modulate inflammation in the surgical
bed. Along with these core surgical products, AxoGen also offers
AcroVal® Neurosensory & Motor Testing System and AxoTouch®
Two-Point Discriminator. These evaluation and measurement tools
assist health care professionals in detecting changes in sensation,
assessing return of sensory, grip, and pinch function, evaluating
effective treatment interventions, and providing feedback to
patients on peripheral nerve function. The AxoGen portfolio of
products is available in the United States, Canada, the United
Kingdom, and several other European and international
countries.
Cautionary Statements Concerning
Forward-Looking Statements This Press Release contains
“forward-looking” statements as defined in the Private Securities
Litigation Reform Act of 1995. These statements are based on
management's current expectations or predictions of future
conditions, events, or results based on various assumptions and
management's estimates of trends and economic factors in the
markets in which we are active, as well as our business plans.
Words such as “expects,” “anticipates,” “intends,” “plans,”
“believes,” “seeks,” “estimates,” “projects,” “forecasts,”
“continue,” “may,” “should,” “will,” and variations of such words
and similar expressions are intended to identify such
forward-looking statements. The forward-looking statements may
include, without limitation, statements regarding our assessment on
our internal control over financial reporting, our growth, our 2018
and 2019 guidance, product development, product potential,
financial performance, sales growth, product adoption, market
awareness of our products, data validation, our visibility at and
sponsorship of conferences and educational events. The
forward-looking statements are subject to risks and uncertainties,
which may cause results to differ materially from those set forth
in the statements. Forward-looking statements in this release
should be evaluated together with the many uncertainties that
affect AxoGen's business and its market, particularly those
discussed in the risk factors and cautionary statements in AxoGen's
filings with the Securities and Exchange Commission.
Forward-looking statements are not guarantees of future
performance, and actual results may differ materially from those
projected. The forward-looking statements are representative only
as of the date they are made and, except as required by law, AxoGen
assumes no responsibility to update any forward-looking statements,
whether as a result of new information, future events, or
otherwise.
Contacts:AxoGen, Inc.Kaila Krum, Vice
President, Investor Relations and Corporate
Developmentkkrum@axogeninc.comInvestorRelations@AxoGenInc.com
Solebury TroutBrian
Korb646.378.2923bkorb@troutgroup.com
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Apr 2023 to Apr 2024